Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions

Teva Pharmaceuticals

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: Hyzaar®

Drug: Losartan potassium/Hydrochlorothiazide

Study type

Interventional

Funder types

Industry

Identifiers

NCT01149486

R04-080

Details and patient eligibility

About

The object of this study was to compare the relative bioavailability (rate and extent of absorption) of 100/25 mg Losartan potassium/Hydrochlorothiazide Tablets manufactured by Teva Pharmaceutical Industries Ltd. and distributed by Teva Pharmaceuticals USA with that of Hyzaar® 100/25 mg Tablets distributed by Merck & Co., Inc. following a single oral dose (1 x 100/25 mg tablet) in healthy adult subjects administered under fasting conditions.

Full description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA Bioequivalence Statistical Methods

Enrollment

20 patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy men and women, 18-45 years of age (inclusive).
Body mass index should be less than or equal to 30
Screening procedures completed within 28 days prior to dosing.
If female and:
- of child bearing potential, is practicing an acceptable barrier method of birth control for the duration of the study
- is postmenopausal for at least 1 year
- is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)

Exclusion criteria

Subjects with a recent history of drug or alcohol abuse or addiction.
Subjects with the presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the clinical investigators).
Subjects whose clinical laboratory test values the accepted reference range and when confirmed on re-examination are deemed to be clinically significant.
Subjects demonstrating a positive hepatitis B surface antigen screen, a positive hepatitis C antibody screen, or a reactive HIV antibody screen.
Subjects demonstrating a positive drug abuse screen when screened for the study.
Female subjects demonstrating a positive pregnancy screen.
Female subjects who are currently breastfeeding.
Subjects who have used implanted or injected hormonal contraceptives anytime during the 180 days prior to study dosing or hormonal contraceptives within 14 days of dosing will not be allowed to participate.
Subjects with a history of allergic response(s) to losartan, hydrochlorothiazide or related drugs.
Subjects with a history of clinically significant allergies including drug allergies.
Subjects with a clinically significant illness during the 4 weeks prior to dosing (as determined by the clinical investigators).
Subjects who have taken any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to dosing.
Subjects who have used tobacco products within 90 days of Period 1 dose administration.
Subjects who report donating greater than 150 mL of blood within 14 days prior to dosing.
Subjects who report receiving any investigational drug within 28 days prior to dosing.
Subjects who report taking any systemic prescription medication in the 14 days prior to dosing.
Subjects who report an intolerance of direct venipuncture.
Subjects who report consuming an abnormal diet within the 28 days prior to dosing.